On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and weight-loss tirzepatide injection products (Mounjaro and ...
Lexaria intends to add a 5th study arm - using DehydraTECH-tirzepatide in an oral capsule - to its 12-week human study already underway in Australia (study GLP-1-H24-4). In that study arm ...
Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...